NPCE — Neuropace Income Statement
0.000.00%
Last trade - 00:00- $365.03m
- $371.80m
- $79.91m
- 46
- 13
- 94
- 50
Annual income statement for Neuropace, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 41.1 | 45.2 | 45.5 | 65.4 | 79.9 |
| Cost of Revenue | |||||
| Gross Profit | 30.3 | 33.4 | 32.5 | 48.1 | 59.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 54.2 | 68.9 | 86.3 | 92.6 | 102 |
| Operating Profit | -13.1 | -23.7 | -40.8 | -27.2 | -21.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -24.3 | -36.1 | -47.1 | -33 | -27.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -24.3 | -36.1 | -47.1 | -33 | -27.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -24.3 | -36.1 | -47.1 | -33 | -27.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -24.1 | -36.1 | -47.1 | -33 | -27.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.04 | -2.17 | -1.91 | -1.27 | -0.932 |
| Dividends per Share |